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Abstract: 
 
Background: Intramuscular depot medroxyprogesterone acetate (DMPA-IM) has known physical 
side effects including changes in bleeding. A lower dose, subcutaneous formulation (DMPA-SC) 
is available with a similar side effect profile among adult women; however, side effect data are 
lacking among adolescent women. We compare DMPA-IM and DMPA-SC with respect to 
physical and sexual side effects among adolescent women, and describe changes in side effect 
expectations and experiences between first and second injections. 
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Article: 
 
Background: Intramuscular depot medroxyprogesterone acetate (DMPA-IM) has known physical 
side effects including changes in bleeding. A lower dose, subcutaneous formulation (DMPA-SC) 
is available with a similar side effect profile among adult women; however, side effect data are 
lacking among adolescent women. We compare DMPA-IM and DMPA-SC with respect to 
physical and sexual side effects among adolescent women, and describe changes in side effect 
expectations and experiences between first and second injections. 
 
Methods: Study participants (SP) are 14-21 year old women (N=55) initiating DMPA. SP were 
recruited from primary care adolescent medicine clinics in a Midwest, urban setting and 
randomized to receive DMPA-IM or DMPA-SC at enrollment. Using a cross-over design, at 3-
month follow-up they received the alternate formulation. At 6-month follow-up they chose and 
received their preferred formulation. SP completed self-administered surveys before each 
injection including 11-pt Likert items of current level of worry, concern about birth control side 
effects, and expected side effects of DMPA (changes in menstrual pattern, pain, weight, and 
sexual interest and enjoyment). At the time of the second and third DMPA injections, SP 
reported experience (no/yes) of these same side effects and of headache, mood changes, and hair 
loss. Descriptive statistics and difference in means t-tests (SPSS 17.0) and logistic regression 
(SUDAAN 10.0) were used. Effects are significant at p<0.05; analyses were limited to SP with 
three study visits (expectation and experience data contributed on both DMPA-IM and DMPA-
SC), as each SP serves as her own control. The study protocol was approved by the university's 
IRB. 
 
Results: Thus far, 28 SP, ages 14-19 years (mean 16), have contributed data for this analysis. At 
enrollment, SP expectations [mean(sd)] of side effects were highest for weight gain [6.5(3.4)], 
amenorrhea [6.0(3.8)], and decreased menstrual pain [5.6(4.1)]. At the second injection, 
expectations were highest for amenorrhea [6.2(3.3)], weight gain [6.0(3.4)], and irregular 
bleeding [5.6(3.6)]. No statistically significant differences were found between side effects 
experienced with DMPA-SC and DMPA-IM. The experienced side effects differed between the 
first and second injections as follows: increased bleeding (1st = 43%, 2nd = 18%), irregular 
bleeding (1st = 29%, 2nd = 7%), and decrease in sexual interest (1st = 3.6%, 2nd = 21.4%.) 
Experience of the remaining side effects were similar for both injections. In regression analysis, 
experience of adverse events were not predicted by DMPA formulation or injection sequence, 
expectation of side effects, previous menstrual history, general worry, or concern about side 
effects. 
 
Conclusions: Experience of DMPA side effects among adolescent women do not differ between 
IM and SC formulations, but do change with subsequent DMPA injection. While young women 
appropriately anticipate physical side effects (likely due to contraceptive counseling), sexual side 
effects are unexpected, despite being common. Future research and clinical counseling should 
include both physical and sexual side effects of DMPA. 
 
